The Emerging Role of Endoscopists in Treating Unresectable Pancreatic Cancer

Adrianne Tsen, Matthew Van Norman, Sreedevi Atluri, Laura Rosenkranz

Research output: Contribution to journalReview articlepeer-review


Pancreatic adenocarcinoma is the eighth leading cause of cancer deaths worldwide in men and ninth leading cause in women. Surgical resection offers the only chance of potential cure; however, only 9.4% of patients present at the localized, resectable stage, whereas the rest present at the locally advanced or metastatic, unresectable stages. Because of the guarded outcomes following systemic chemoradiation and the associated systemic toxicities, locoregional therapies have recently gained popularity. Various endoscopic techniques (endoscopic ultrasound [EUS]-guided ablative therapies, fine-needle instillation of antitumor agents, stereotactic body radiation therapy with EUS-guided fiducial marker placement, and EUS-guided brachytherapy) have been explored over the past several years. Endoscopic therapy plays a role in the treatment of unresectable pancreatic adenocarcinoma. Its minimal invasiveness and increased precision of delivering oncologic treatments under EUS guidance render it as a favorable option for patients who do not benefit from surgical resection. New endoscopic therapies are currently under investigation, and the emerging role of the endoscopist in the treatment of unresectable pancreatic cancer continues to grow.

Original languageEnglish (US)
Pages (from-to)839-849
Number of pages11
Issue number7
StatePublished - Aug 1 2017


  • antitumor agents
  • brachytherapy
  • endoscopic ultrasound
  • fiducial markers
  • pancreatic adenocarcinoma
  • radiofrequency ablation

ASJC Scopus subject areas

  • Endocrinology
  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Hepatology


Dive into the research topics of 'The Emerging Role of Endoscopists in Treating Unresectable Pancreatic Cancer'. Together they form a unique fingerprint.

Cite this